The FSHD Society Celebrates Fulcrum's Milestone in the Fight Against FSHD

Fulcrum Therapeutics has announced successful completion of patient enrollment in REACH Phase 3 trial RANDOLPH, Mass., Sept. 8, 2023 /PRNewswire-PRWeb/ -- The FSHD Society, a leading advocate and partner in the quest to find treatments for Facioscapulohumeral Muscular Dystrophy (FSHD), is...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news